News

GAIA BioMedicine Initiates Development of Proprietary Cell Processing Center (CPC) at “f-labs Kyushu University Hospital” – Paving the Way for Commercial Production of Innovative Cancer Therapies –

GAIA-102 interim data in pediatric neuroblastoma to be presented at the 67th Annual Meeting of the Japanese Society of Pediatric Hematology/Oncology

Interim report on physician-initiated clinical trial of GAIA-102 for peritoneal dissemination received Excellent Presentation Award at the 97th Annual Meeting of the Japanese Gastric Cancer Association

Prof. Yoshikazu Yonemitsu will present at the 31st Annual Meeting of Japan Society of Gene and Cell Therapy

The progress report on the safety and clinical efficacy of GAIA-102 against pediatric solid malignant tumors will be presented at the 66th Annual Meeting of the Japanese Society of Pediatric Hematology/Oncology

At the European Society for Medical Oncology 2024, the interim report of the clinical trial for peritoneal dissemination (gastric/pancreatic cancer) will be presented

Notice of Adoption of AMED Grant for Development of Production Methods Aimed at Practical Application of Regenerative Medical Products

At IMMUNOLOGY 2024, research results about GAIA-102 were presented

DLT evaluation of the monotherapy cohort for GAIA-102 in the clinical trial for pediatric patients with relapsed/refractory solid malignancies has been completed

Research results related to the cultivation technology of GAIA-102 received the Excellent Presentation Award at the 23rd Congress of the Japanese Society for Regenerative Medicine